PRT 7732
Alternative Names: PRT-7732Latest Information Update: 20 Aug 2024
At a glance
- Originator Prelude Therapeutics
- Class Antineoplastics; Small molecules
- Mechanism of Action SMARCA2 protein degraders
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Cancer
Most Recent Events
- 12 Aug 2024 USFDA approves IND application for PRT 7732 in Cancer
- 09 Apr 2024 Pharmacodynamics and pharmacokinetics data from the preclinical studies in Cancer released by Prelude Therapeutics
- 05 Apr 2024 Pharmacodynamics data from a preclinical trial in Cancer presented at the 115th Annual Meeting of the American Association for Cancer Research (AACR-2024)